Caxton Associates LP decreased its holdings in shares of Zoetis Inc (NYSE:ZTS) by 43.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,606 shares of the company’s stock after selling 3,505 shares during the quarter. Caxton Associates LP’s holdings in Zoetis were worth $394,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Whittier Trust Co. raised its holdings in Zoetis by 3.2% during the fourth quarter. Whittier Trust Co. now owns 4,039 shares of the company’s stock worth $345,000 after purchasing an additional 124 shares in the last quarter. North Star Investment Management Corp. raised its holdings in Zoetis by 0.6% during the fourth quarter. North Star Investment Management Corp. now owns 22,525 shares of the company’s stock worth $1,927,000 after purchasing an additional 125 shares in the last quarter. Sandy Spring Bank raised its holdings in Zoetis by 0.4% during the fourth quarter. Sandy Spring Bank now owns 29,716 shares of the company’s stock worth $2,542,000 after purchasing an additional 125 shares in the last quarter. InterOcean Capital LLC raised its holdings in Zoetis by 5.0% during the fourth quarter. InterOcean Capital LLC now owns 2,945 shares of the company’s stock worth $252,000 after purchasing an additional 139 shares in the last quarter. Finally, Harvest Management LLC raised its holdings in Zoetis by 8.0% during the fourth quarter. Harvest Management LLC now owns 2,700 shares of the company’s stock worth $231,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 89.98% of the company’s stock.
Several research analysts recently issued reports on the stock. Stifel Nicolaus raised shares of Zoetis from a “hold” rating to a “buy” rating and increased their price target for the stock from $97.00 to $110.00 in a report on Monday, March 4th. Zacks Investment Research raised shares of Zoetis from a “sell” rating to a “hold” rating in a report on Saturday, February 16th. BMO Capital Markets increased their price target on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a report on Monday, February 25th. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus target price of $98.85.
Shares of Zoetis stock opened at $96.91 on Friday. Zoetis Inc has a 12-month low of $77.00 and a 12-month high of $97.95. The company has a debt-to-equity ratio of 2.95, a current ratio of 3.60 and a quick ratio of 2.46. The stock has a market capitalization of $46.40 billion, a price-to-earnings ratio of 30.96, a P/E/G ratio of 1.74 and a beta of 0.92.
Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The company had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period last year, the company posted $0.69 earnings per share. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc will post 3.46 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be issued a $0.164 dividend. The ex-dividend date of this dividend is Wednesday, April 17th. This represents a $0.66 dividend on an annualized basis and a yield of 0.68%. Zoetis’s dividend payout ratio (DPR) is presently 21.09%.
Zoetis announced that its board has approved a stock repurchase plan on Wednesday, December 12th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: What are trading strategies for the 52-week high/low?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.